Gut health hope: probiotic trial launches for Sjogren's
NCT ID NCT06297213
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial will test an oral probiotic called R-2487 in 36 adults with Sjogren's syndrome. The main goal is to see if the probiotic is safe and tolerable. Researchers will also check for changes in disease activity and inflammation using blood and stool samples. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
R-2487 (a probiotic taken by mouth)
What this could lead to
If this works, it could point toward a new way to manage Sjogren's syndrome by improving gut health and reducing inflammation.
What could go wrong
This is a very early Phase 1 trial with only 36 people, focused on safety. It is too soon to know if the probiotic will actually help symptoms, and it may not show any benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••